 Heidelberg, Germany, November 4, 2020 Affimed N.V. Nasdaq: AFMD, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the companys management will participate in the following investor conferences during the month of November: 